Compare Novavax Inc (NVAX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Trip.com Group Ltd — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Trip.com Group Ltd trades at $38.9 (market cap $23.75B). The key difference: Trip.com Group Ltd is far larger — about 13× Novavax Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Trip.com Group Ltd for 79 Days on average.
| NVAX | TCOM | |
|---|---|---|
Market Cap | $1.82B | $23.75B |
Volume | 6,198,505 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.56 | $78.96 |
52-Week Low | $6.22 | $37.96 |
Typical Hold Time | 59 Days | 79 Days |
Enterprise Value | $1.39B | $15.91B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Trip.com (TCOM) trades at $37.96, down 0.34% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 earnings of $1.07 per share, beating expectations, with revenue reaching $62.41 billion in 2025 and net income margin of 36.9%. Recent regulatory challenges and market volatility have pressured the stock, though analyst consensus remains overwhelmingly positive with a $56.64 price target.
The stock presents a value opportunity with attractive valuation multiples (P/E 7.34, EV/EBITDA 3.43) but faces near-term headwinds from regulatory changes and competitive pressures. Strong cash flow generation and international expansion provide upside potential, though investors should monitor execution risks amid shifting market dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
